Health Care · Surgical & Medical Instruments & Apparatus · NYSE · CIK 1192448 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $189.55 · Day +2.93% · Mkt cap $10.9B · 1Y +108.2% · Off 52W high −0.3% · Vol (1Y) 52.7% Price2023-08-21 → 2026-08-19 GKOS close: $73 on 2023-08-21 to $190 on 2026-08-19. Split-adj closes · 240 of 2,802 · price returnⓘ At a glance | Short interest6.1% of sh out | | Days to cover3.6d | | 13F net flow (QoQ)−0.27% | | Top-10 13F concentration54.4% | | Next report (est.)2026-10-28 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$612.8M | | Earnings (TTM)-$188.0M | | ROE−26.4% | | Net margin−37.0% | | ROIC−27.1% | | Sales growth 3Y21.5% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+67.9% | | 1Y+108.2% | | 3Y+159.9% | | 5Y+299.6% | | 10Y+524.5% | | Since incept. (ann.)+17.6% |
Total return · from 2015-06-25ⓘ Risk | Ann. volatility (1Y)52.7% | | Ann. volatility (3Y)48.7% | | Sharpe (1Y)1.69 | | Sharpe (3Y)0.91 | | Max drawdown (1Y)−28.4% | | Max drawdown (3Y)−53.7% | | Beta (3Y vs SPY)0.98 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 9.1M | $979M | 15.65% | −0.8% | | JANUS HENDERSON GROUP PLC | 5.3M | $576M | 9.21% | +77.2% | | PRIMECAP MANAGEMENT CO/CA/ | 3.4M | $363M | 5.80% | −0.2% | | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.2M | $345M | 5.52% | new | | VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $270M | 4.32% | new | | STATE STREET CORP | 2.2M | $235M | 3.76% | +2.8% | | AMERIPRISE FINANCIAL INC | 1.6M | $173M | 2.77% | −23.5% | | ALLIANCEBERNSTEIN L.P. | 1.4M | $158M | 2.41% | −15.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-07-29 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-07-29 | −$0.31 | — | $185.6M | +49.5% | | 2026-03-31 | 2026-04-29 | −$0.34 | — | $150.6M | +41.2% | | 2025-12-31 | 2026-02-17 | — | — | $143.1M | +35.7% | | 2025-09-30 | 2025-10-29 | −$0.28 | — | $133.5M | +38.1% |
As-reported XBRL · next 2026-10-28 est.ⓘ Segment mixFY2025 (ended Dec 2025) Development And Commercialization Of Ophthalmic Therapies 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
